CD8A and neoplasm: The most pronounced trend observed following M3258 treatment was a reduction in M2 macrophages (p = 0.0996); less prominent reductions were observed for tumor abundance of CD4+ T cells (p = 0.247) and CD8+ T cells (p = 0.247).